ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,318.86
-0.05%
Dow Jones
39,810.41
-0.16%
US Dollar vs MXN
16.61935
-0.01%
Brent Oil
82.075
-0.45%
Bitcoin
70,399.99
0.38%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Lumos Pharma Inc (LUMO)

  7. Lumos Pharma Inc (LUMO) Noticias

LUMO Lumos Pharma Inc

2.6595
0.1395 (5.54%)
Última actualización: 10:15:46
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Lumos Pharma Inc LUMO NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.1395 5.54% 2.6595 10:15:46
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
2.53 2.5164 2.6595 2.52
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
20/5/202415:05GLOBELumos Pharma Announces Abstracts Accepted for Presentation..
15/5/202408:57EDGAR2Form 8-K - Current report
14/5/202415:15GLOBELumos Pharma Announces Positive End-of-Phase 2 Meeting with..
09/5/202413:51GLOBELumos Pharma to Report First Quarter 2024 Financial Results..
18/4/202415:05GLOBELumos Pharma Announces Abstracts Accepted for Presentation..
20/3/202407:00GLOBELumos Pharma Announces that the USPTO Has Granted Patent..
07/3/202415:48EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
07/3/202415:44EDGAR2Form 8-K - Current report
07/3/202415:01GLOBELumos Pharma Reports Full Year 2023 Financial Results and..
26/2/202408:00GLOBELumos Pharma to Report Full Year 2023 Financial Results and..
07/2/202416:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202415:02EDGAR2Form 144 - Report of proposed sale of securities
05/2/202416:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202416:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202416:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202416:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202416:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202415:05GLOBELumos Pharma to Participate in Oppenheimer’s 34th Annual..
10/1/202418:03EDGAR2Form 3 - Initial statement of beneficial ownership of..
04/1/202415:34EDGAR2Form 8-K - Current report
04/1/202415:05GLOBELumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to..
29/11/202315:30EDGAR2Form SC 13D/A - General statement of acquisition of..
21/11/202315:15GLOBELumos Pharma to Host Virtual Key Opinion Leader Webinar to..
20/11/202315:05GLOBELumos Pharma Announces Participation in the Piper Sandler..
15/11/202315:38EDGAR2Form 8-K - Current report
07/11/202317:24DJNLumos Pharma Shares Than Double After Hormone Deficiency..
07/11/202316:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202315:42EDGAR2Form 8-K - Current report
07/11/202315:35GLOBELumos Pharma Reports Third Quarter 2023 Financial Results..
07/11/202315:08EDGAR2Form 8-K - Current report
07/11/202315:01GLOBELumos Pharma Announces Topline Data from Phase 2..
26/9/202315:34EDGAR2Form 8-K - Current report
26/9/202308:00GLOBELumos Pharma Announces New Data and Analysis of 15 Subjects..
14/9/202307:00GLOBELumos Pharma Announced Abstract Accepted for Oral..
07/9/202315:34GLOBELumos Pharma Announces Participation in Investor Conferences..
22/8/202308:00GLOBEIndependent Panel of Renowned Pediatric Endocrinologists to..
10/8/202308:32EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/8/202315:36EDGAR2Form 8-K - Current report
09/8/202315:01GLOBELumos Pharma Reports Second Quarter 2023 Financial Results,..
03/8/202315:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/8/202315:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/8/202314:54EDGAR2Form 144 - Report of proposed sale of securities
26/7/202308:00GLOBELumos Pharma to Report Second Quarter 2023 Financial Results..
12/7/202307:00GLOBELumos Pharma to Participate in the Oppenheimer 2023 Montauk..
28/6/202315:26EDGAR2Form 8-K - Current report
28/6/202315:01GLOBELumos Pharma Announces Departure of Chief Medical Officer
21/6/202308:00GLOBELumos to Highlight New LUM-201 Data and Analysis Presented ..
31/5/202307:00GLOBELumos Pharma to Participate in the Upcoming 2023 BIO..
25/5/202307:00GLOBELumos Pharma Announces Abstracts Accepted for Oral..

Su Consulta Reciente

NASDAQ
LUMO
Lumos Pharma
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados